Providence, RI, United States of America

Jack A Elias

This inventor holds 16 USPTO granted patents and 17 published patent applications and 2 EPO patents. Top assignees: Brown University, Yale University, Csl Limited. Active years: 2007-2026.

USPTO Granted Patents = 16 (Patent Applications = 17)

% Patents Active = 93.8

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 44(Granted Patents)

Location History:

Woodbridge, CT (US) (2007 - 2014)
Providence, RI (US) (2018 - 2023)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12649792 - BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND PD1 WITH ENHANCED T CELL-MEDIATED CYTOTOXIC EFFECTS ON TUMOR CELLS (2026-06-09),

2. 11717528 - Methods and compositions relating to the treatment of fibrosis (2023-08-08),

3. 11667726 - Methods and compositions relating to bispecific anti-CHI3L1 antibody reagents for the treatment of cancer (2023-06-06),

4. 11667725 - Methods and compositions relating to anti-CHI3L1 antibody reagents for the treatment of cancer (2023-06-06),

5. 11478530 - Methods for decreasing chord length (2022-10-25),

6. 11219630 - Methods and compositions relating to the treatment of fibrosis (2022-01-11),

7. 10766968 - Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer (2020-09-08),

8. 10752700 - Methods and compositions relating to anti-CHI3L1 antibody reagents to treat nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NFALD) or metabolic syndrome (2020-08-25),

9. 10253111 - Methods and compositions relating to anti-Chi3l1 antibody reagents (2019-04-09),

10. 9994905 - Methods for the diagnosis and treatment of pulmonary fibrosis in subjects with hermansky pudlak syndrome (2018-06-12),

11. 8679503 - Methods, compositions and kits relating to chitnases and chitnase-like molecules and inflammation disease (2014-03-25),

12. 8642357 - [object Object] (2014-02-04),

13. 8221988 - Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation (2012-07-17),

14. 8182814 - Methods of treating inflammatory airway conditions by inhibition of IL-11 activity (2012-05-22),

15. 7943130 - Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation (2011-05-17),

Title: The Innovative Contributions of Jack A Elias

Introduction

Jack A Elias, based in Providence, RI, is a notable inventor recognized for his significant contributions to medical research and treatment innovations. With a remarkable portfolio of 15 patents, Elias has been instrumental in developing methods that address critical health issues, particularly in the fields of fibrosis and cancer treatment.

Latest Patents

Among his recent works, Elias holds patents for "Methods and compositions relating to the treatment of fibrosis," wherein he explores the use of certain aminoglycosides, such as kasugamycin derivatives, for treating fibrotic diseases. He has also developed innovative "Methods and compositions relating to bispecific anti-CHI3L1 antibody reagents for the treatment of cancer." This patent demonstrates the synergistic effects of combining inhibitors of immune checkpoints with CHI3L1, paving the way for combinatorial therapies aimed at more effective cancer treatments.

Career Highlights

Elias has held prominent positions at esteemed institutions, including Brown University and Yale University. His work in these academic environments has facilitated groundbreaking research that translates into practical medical applications.

Collaborations

Throughout his career, he has collaborated with notable coworkers such as Chun Geun Lee and Bing Ma, enhancing the scope and impact of his research efforts. These partnerships have contributed to the advancement of knowledge in their respective fields.

Conclusion

In summary, Jack A Elias has made significant strides in medical innovation through his extensive patent portfolio. His work not only reflects his dedication as an inventor but also highlights the importance of collaborative efforts in advancing health sciences. Eliascs’ contributions continue to inspire future innovations in treatment methodologies.